Thyroid Eye Disease Market Expands With Targeted Therapies and Improved Diagnosis

Thyroid Eye Disease Market Overview

Thyroid Eye Disease (TED) is an autoimmune inflammatory condition affecting the tissues surrounding the eyes and is strongly associated with thyroid disorders, particularly Graves’ disease. The condition can cause orbital inflammation, eyelid retraction, double vision, periorbital swelling, and proptosis, potentially affecting both appearance and vision. According to DelveInsight, the thyroid eye disease market is being shaped by increasing disease awareness, improved diagnosis, expanding therapeutic options, and the emergence of targeted biologic treatments. The report covers the United States, EU4 countries, the United Kingdom, and Japan, with a study period from 2020 to 2034.

The disease represents the major extrathyroidal manifestation of Graves’ disease and can substantially reduce patients’ quality of life. Its clinical presentation ranges from mild ocular discomfort and dryness to severe manifestations that can threaten vision. Because mild and moderate cases may be overlooked or confused with other orbital or inflammatory conditions, the actual patient population can be difficult to identify. This diagnostic challenge has historically contributed to underdiagnosis and delayed treatment.

Thyroid Eye Disease Epidemiology and Patient Burden

The epidemiological landscape provides important insights into the future development of the thyroid eye disease treatment market. DelveInsight estimates that the total prevalence of TED across the seven major markets was approximately 2.386 million cases in 2022, with the number projected to rise during the forecast period. The United States represented the largest share, with approximately 1.012 million prevalent cases in 2022, accounting for about 42% of the total 7MM population. Germany represented approximately 13%, while Japan accounted for around 8%.

The disease also demonstrates a notable gender distribution, with women representing approximately 80% of diagnosed prevalent cases across the 7MM. The inflammatory phase commonly lasts three to six months but can persist for considerably longer, followed by an inactive fibrotic phase. Reactivation can occur after the disease becomes inactive, further complicating long-term management.

The relationship between TED and autoimmune thyroid disorders also creates an important adjacent opportunity for companies evaluating the hashimotos disease market and broader autoimmune thyroid indications. Although TED is most strongly associated with Graves’ disease, thyroid autoimmunity and abnormal thyroid function remain important considerations during diagnosis and patient management.

Thyroid Eye Disease Diagnosis and Treatment Landscape

Diagnosing TED requires clinical assessment alongside thyroid-related laboratory testing and, when appropriate, orbital imaging. Diagnosis can be relatively straightforward in patients with bilateral proptosis and established hyperthyroidism but becomes more complicated among euthyroid or hypothyroid patients, particularly those presenting with unilateral proptosis. Testing for TSH receptor antibodies, including thyroid-stimulating immunoglobulins and thyrotropin-binding inhibitory immunoglobulins, can support diagnosis. CT and MRI may also help identify orbital abnormalities and exclude alternative causes.

Early identification is particularly important because intervention during the active inflammatory phase may improve long-term outcomes. However, mild disease can remain undiagnosed, limiting access to timely treatment. Increasing awareness among clinicians and patients is therefore expected to support diagnosis and contribute to market expansion.

The treatment landscape has evolved considerably. Before the introduction of targeted therapy, corticosteroids, immunosuppressants, orbital radiation, and off-label biologics such as rituximab and tocilizumab were commonly used for moderate-to-severe active disease. DelveInsight notes that these approaches represented a market of approximately USD 37 million across the 7MM before 2019.

Thyroid Eye Disease Market Drivers

One of the strongest growth factors is the increasing recognition of untreated and undertreated TED. The condition can produce persistent ocular symptoms, cosmetic changes, functional impairment, and, in severe cases, sight-threatening complications. As awareness improves, more patients are expected to undergo appropriate evaluation and enter treatment pathways.

The approval of TEPEZZA (teprotumumab) in the United States significantly changed the therapeutic landscape. DelveInsight identifies TEPEZZA as the only FDA-approved therapy specifically indicated for TED in the report. The treatment targets insulin-like growth factor-1 receptor (IGF-1R), a pathway implicated in the disease process. Clinical benefits include reductions in proptosis and diplopia as well as improvements in disease activity and quality of life.

This targeted approach has helped establish biologics as an important component of the evolving us thyroid disorder market, while also encouraging pharmaceutical companies to investigate alternative mechanisms, administration routes, and treatment strategies.

Another major driver is the unmet need among patients who require more convenient, effective, or durable treatment. Only a portion of patients with TED develop acute moderate-to-severe disease requiring drug therapy. DelveInsight estimates that approximately 20% of cases are treated for acute disease, suggesting substantial potential for market expansion as diagnosis improves and safer and more effective therapies become available.

Thyroid Eye Disease Market Barriers

Despite substantial commercial potential, several challenges may restrict market growth. The heterogeneous presentation of TED makes diagnosis difficult, particularly in patients with mild, unilateral, euthyroid, or atypical disease. Delayed diagnosis can prevent patients from receiving treatment during the active inflammatory stage when therapeutic intervention may be most beneficial.

Treatment-related safety concerns and administration requirements can also influence adoption. Conventional corticosteroid therapy is associated with significant adverse effects, while intravenous biologic treatment can require repeated healthcare visits. These limitations create opportunities for alternative delivery methods but can also contribute to treatment discontinuation or reluctance among patients and physicians.